Treatment for Hypertrophic Cardiomyopathy with Asymmetric Septal Hypertrophy

Initial Medical Management

The American College of Cardiology recommends beta-blockers as the first-line medical therapy for symptomatic patients with hypertrophic cardiomyopathy (HCM) with asymmetric septal hypertrophy, titrated to achieve a resting heart rate less than 60-65 bpm 1, 2
Beta-blockers should be started as initial therapy for all symptomatic patients, regardless of whether left ventricular outflow tract obstruction (LVOTO) is present, and titrated to maximum tolerated doses targeting a resting heart rate <60-65 bpm 1, 2
The American Heart Association suggests using beta-blockers with caution in patients with sinus bradycardia or severe conduction disease 2
Beta-blockers reduce systolic overcontraction and improve symptoms of dyspnea, angina, and syncope in patients with HCM 3

If patients do not respond to beta-blockers, have intolerable side effects, or have contraindications, the American College of Cardiology recommends switching to verapamil, starting at low doses and titrating up to 480 mg/day as tolerated 1, 2
Verapamil should be used with extreme caution in patients with high gradients (≥50 mm Hg at rest), advanced heart failure, or sinus bradycardia 1, 2
The American Heart Association suggests adding disopyramide combined with a beta-blocker or verapamil for patients with obstructive HCM who remain symptomatic despite first-line therapy 1, 2, 3
Disopyramide should never be used alone without beta-blockers or verapamil in patients with atrial fibrillation, as it may enhance atrioventricular conduction and increase ventricular rate 2, 3

The American College of Cardiology warns that dihydropyridine calcium channel blockers (e.g., nifedipine, amlodipine) are potentially harmful in patients with resting or provocable LVOT obstruction 1, 2
Vasodilators (ACE inhibitors, ARBs) should be used cautiously or avoided in obstructive HCM, as they may worsen symptoms by reducing afterload 1, 2
Digitalis is potentially harmful for dyspnea in HCM patients without atrial fibrillation 2
Positive inotropic drugs (dopamine, dobutamine, norepinephrine) are potentially harmful for acute hypotension in obstructive HCM 3

Septal reduction therapy should only be considered for patients meeting specific clinical, hemodynamic, and anatomic criteria, including severe dyspnea or chest pain (NYHA functional class III or IV) and symptoms refractory to optimal medical therapy 3, 4
Surgical septal myectomy is the first consideration for the majority of eligible patients when performed at experienced centers 3
Alcohol septal ablation can be beneficial when surgery is contraindicated or risk is unacceptable due to serious comorbidities or advanced age 3, 4

For acute hypotension in obstructive HCM, the American College of Cardiology recommends using intravenous phenylephrine and administering cautious IV fluid boluses of 250-500 mL normal saline over 30-60 minutes if needed 2
If ejection fraction falls to ≤50%, treatment should be according to evidence-based heart failure therapy, including ACE inhibitors, ARBs, and beta-blockers 3, 7

Repeat echocardiography should be performed every 1-2 years in stable patients to assess degree of hypertrophy, LVOTO, mitral regurgitation, and myocardial function 8
Comprehensive sudden cardiac death risk stratification should be performed at initial evaluation and periodically thereafter 7
Screening for atrial fibrillation is necessary, as it requires anticoagulation in HCM regardless of CHA₂DS₂-VASc score 1, 2